Venture&Growth Archives - Gilde Healthcare

Neuigkeiten & Einblicke
Venture&Growth

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone. Volta Medical, a pioneering health-tech company developing AI based solutions to assist electrophysiologists, announced positive results from the transatlantic, multicenter, randomized, controlled, superiority trial titled...
21. Mai 2024

Gilde Healthcare co-leads $100M equity financing in Karius

test Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and was joined by new investor Seventure and existing investors Softbank Vision Fund 2, General Catalyst, HBM and others. This investment […]

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

test Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of Cardiology’s 73rd Annual Scientific Congress in Atlanta, GA this week. The data was also released online, ahead of print, in […]

Gilde Healthcare co-leads oversubscribed €54 Million Series B round of Argá Medtech

Argá Medtech, a company developing a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation (AF), announced it closed a €54M oversubscribed Series B raise co-led by Gilde Healthcare with existing investors, Advent Life Sciences (U.K.) and Earlybird Venture Capital (Germany), as well as an...

Gilde Healthcare leads $125 Million Equity Financing of Mainstay Medical

Funding to accelerate commercial growth and expand clinical and health economic evidence for ReActiv8® Restorative NeuromodulationTM System Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross proceeds of US$125 million. Mainstay intends to use the funds to support the company’s continued...

Amphista Therapeutics announces in vivo efficacy and CNS activity of its protein degraders

First demonstration of efficacy in disease-relevant in vivo models for an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader Deep degradation of target protein is achieved in a rapid, sustained, and highly selective manner Successful achievement of efficient CNS delivery for multiple degraders and demonstration of significant...

James Leech Joins Moximed as Chief Financial and Strategy Officer

Leech brings expertise in financing and scaling growth-stage medtech companies. Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that James Leech has joined the company as Chief Financial and Strategy Officer. “James adds...

Gilde Healthcare company AM-Pharma initiates Phase 2 trial of Ilofotase alfa for cardiac surgery-associated renal damage

Trial will evaluate ilofotase alfa as a treatment to prevent renal damage in at-risk patients following open heart surgery Ilofotase alfa’s clinical record of renal protective effects supports therapeutic potential in underserved and high-need indication AM-Pharma B.V. today announced that the first patients have been treated in...

Gilde Healthcare announces Calypso to be acquired by Novartis for up to USD 425M

The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastro-intestinal and rheumatology indications Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of auto-immune indications Gilde Healthcare acted...
Loading...
These were all messages
d51ae2b6c7